Drug Trial Radar · NCT07219615
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Dec 25, 2026
Study completion Apr 23, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are used to stop the body's "allergy alarm system" from overreacting. Chronic spontaneous urticaria is a disease that causes itchy hives and swellings in the deep layers of skin and fatty tissue just underneath the skin that come and go without a clear reason. This study will look at both the 50 milligrams (mg) once daily (QD) oral dose and 100 milligrams (mg) once daily (QD) oral dose and compare them to placebo (pill with no active medicine). This study is seeking participants who: * Are 18 years of age or older * Have a diagnosis of chronic spontaneous urticaria for 3 months or more that has not been controlled well with antihistamine treatment. * Do not have any other skin conditions associated with chronic itching or itching caused mainly by known triggers. * Are willing to stop all other treatments that they may be taking for chronic spontaneous urticaria other than a second-generation antihistamine (sgAH). About 150 participants will take part in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive either the 50 mg dose or 100 mg dose or placebo, taken by mouth once daily for 12 weeks( Period A). Thereafter the participants on 50 mg and 100 mg will continue on their doses while the participants receiving placebo will be switched to 100mg for an additional 12 weeks (Period B). The 2 doses of ritlecitinib in this study will be compared to each other and to the placebo. This will help to see if the 50 mg and/or 100 mg dose of ritlecitinib is safe and effective. Participants will be in this study for about 8 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * Physical examinations, * Hearing tests, * Blood tests, * X-ray, * ECG (electrocardiogram), * Participants will also be asked to complete questionnaires every day about their chronic spontaneous urticaria in an electronic diary.
Conditions
- Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mgDrug
50 mg Capsule
Ritlecitinib 100 mgDrug
100 mg Capsule
Placebo - 50 mgDrug
Matching Capsule
Placebo - 100 mgDrug
Matching Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12Time frame: Week 12
- Incidence of Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events leading to discontinuationTime frame: Week 12
Locations
77 sites in 10 countries. Site status is shown where the registry gives one.
Saguaro Dermatology - Phoenix
Phoenix, Arizona · Recruiting
Acuro Research, Inc.
Little Rock, Arkansas · Recruiting
Kern Research, Inc.
Bakersfield, California · Recruiting
First OC Dermatology Research Inc
Fountain Valley, California · Recruiting
Antelope Valley Clinical Trials
Lancaster, California · Recruiting
Ark Clinical Research
Long Beach, California · Recruiting
Skin & Beauty Center - Pasadena
Pasadena, California · Recruiting
Asthma and Allergy Associates, PC
Colorado Springs, Colorado · Recruiting
Asthma and Allergy Center of Chicago
River Forest, Illinois · Recruiting
Chesapeake Clinical Research
White Marsh, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Revival Research Institute, LLC
Troy, Michigan · Recruiting
Equity Medical, LLC
The Bronx, New York · Recruiting
Allergy, Asthma, & Clinical Research Center
Oklahoma City, Oklahoma · Recruiting
Vital Prospects Clinical Research Institute, PC
Tulsa, Oklahoma · Recruiting
Columbia Dermatology & Aesthetics
Columbia, South Carolina · Recruiting
Orion Clinical Research
Austin, Texas · Recruiting
RFSA Dermatology - San Antonio - West Avenue
San Antonio, Texas · Recruiting
Complete Dermatology
Sugar Land, Texas · Recruiting
Medical Center Pulmo - 2018 EOOD
Haskovo, Bulgaria · Recruiting
Diagnostic Consultative Center 1 - Pernik
Pernik, Bulgaria · Recruiting
Diagnostic Consultative Center "Ascendent"
Sofia, Bulgaria · Recruiting
Medical Center Hera EOOD
Sofia, Bulgaria · Recruiting
Medical Center Pulmovision
Sofia, Bulgaria · Recruiting
Diagnostic Consultative Center Aleksandrovska
Sofia, Sofia (stolitsa), Bulgaria · Recruiting
Centre de Recherche Saint-Louis inc.
Québec, Canada · Recruiting
Laser Rejuvenation Clinics Edmonton D.T. Inc
Edmonton, Alberta, Canada · Recruiting
CaRe Clinic
Red Deer, Alberta, Canada · Recruiting
Allergy Centre Research
Mississauga, Ontario, Canada · Recruiting
Allergy Research Canada Inc.
Niagara Falls, Ontario, Canada · Recruiting
DAR Clinical Research
Ottawa, Ontario, Canada · Recruiting
Dar Clinical Research
Ottawa, Ontario, Canada · Recruiting
Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The Third Affiliated Hospital Of Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China · Recruiting
Charite Universitätsmedizin Berlin Campus Benjamin Franklin
Berlin, Germany · Recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.